Search
DEEN
more info

Contact:
Phone:+49 0761 1514 440Fax:+49 0761 1514 460Email:info[at]falkfoundation.org

    Esophagus to Small Intestine

    Inflamm Bowel Dis. 2023;29(11):1741–50

    Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Mohl W, Teich N, Hoffstadt M, Schweitzer A, von der Ohe M, Gauss A, Atreya R, Krause T, Blumenstein I, Hartmann P, Schreiber S; German Inflammatory Bowel Diseases Study Group (GISG)

    Real-world comparative effectiveness of ustekinumab vs. anti-TNF in Crohn’s disease with propensity score adjustment: Induction phase results from the prospective, observational RUN-CD study


    Background: In addition to randomized controlled trials (RCTs), real-world studies on the effectiveness of ustekinumab (UST) in Crohn’s disease (CD) are required inasmuch as RCTs are usually confined to selected patients, which may not represent everyday clinical practice. Within the framework of the prospective real-world RUN-CD registry, a total of approximately 900 CD patients from 44 inflammatory bowel disease centers from all over Germany starting a new therapy with UST or other biologics were screened for a real-world evidence (RWE) comparison of CD patients with UST versus anti-tumor necrosis factor (TNF).
    Methods: A total of 618 CD patients with a non-randomized biological therapy were qualified for this induction phase effectiveness RUN-CD study of UST versus anti-TNF. To reduce selection bias in estimations of treatment effects, the propensity score with inverse probability of treatment weighting was implemented. The results were reported as odds ratio (OR) and 95% confidence interval (CI).
    Results: A total of 339 UST and 279 anti-TNF patients were analyzed. The effectiveness of UST versus anti-TNF, in terms of clinical remission (UST, 65.4% vs. anti-TNF, 63.0%; OR = 1.11; 95% CI: 0.71–1.74) and steroid-free remission (UST, 51.0% vs. anti-TNF, 53.8%; OR = 0.94; 95% CI: 0.60–1.47) was comparable at the end of induction therapy. Similar results were observed in the bio-naive and bio-experienced UST versus anti-TNF groups. For both, the remission rates were higher in the bio-naive than in the bio-experienced groups (p < 0.05).

    Conclusions: In this prospective, observational RUN-CD study, the real-world evidence head-to-head comparison of ustekinumab versus anti-tumor necrosis factor showed similar induction effectiveness in both groups, remarkably higher than those found in prior randomized controlled trials.

    Prof. Dr. B. Bokemeyer, Interdisziplinäres Crohn Colitis Centrum Minden und Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein (UKSH), Kiel, Germany, E-Mail: bernd.bokemeyer@t-online.de

    DOI: 10.1093/ibd/izac271

    Back to overview

    this could be of interest:

    Esophagus to Small Intestine

    Early ileocecal resection for Crohn’s disease is associated with improved long-term outcomes compared with anti-tumor necrosis factor therapy: A population-based cohort study

    Gastroenterology. 2023;165(4):976–85.e3

    Agrawal M, Ebert AC, Poulsen G, Ungaro RC, Faye AS, Jess T, Colombel JF, Allin KH

    Go to article

    Esophagus to Small Intestine

    Thalidomide for recurrent bleeding due to small intestinal angiodysplasia

    N Engl J Med. 2023;389(18):1649–59

    Chen H, Wu S, Tang M, Zhao R, Zhang Q, Dai Z, Gao Y, Yang S, Li Z, Du Y, Yang A, Zhong L, Lu L, Xu L, Shen X, Liu S, Zhong J, Li X, Lu H, Xiong H, Shen Y, Chen H, Gong S, Xue H, Ge Z

    Go to article
    More articles on the topic